The key is choosing the right clinic, right protocol, and expert guidance
Those with seizure disorders may notice increased seizure activity
While both Retatrutide and Tirzepatide represent a new generation of metabolic research, they differ significantly in their chemical structure, regulatory status, and clinical outcomes
Conversely, GLP-1RAs increased the risk of diarrhea, hypoglycemia, vomiting, and nausea
Genital mycotic infections in patients with diabetes
Insulin dose reduction of 20 to 50% at triple agonist initiation is consistent with the approach used in tirzepatide trials: the SURPASS-5 trial (N=475) reduced insulin glargine by 20% at tirzepatide initiation, which reduced hypoglycemia without sacrificing glycemic control